Stock Groups

H.C. Wainwright Bullish on Aridis Pharmaceuticals Covid-19 Antibody Cocktail -Breaking

by Mike Robinson

[ad_1]

© Reuters.

Sam Boughedda

Investing.com — Aridis Pharmaceuticals Inc ‘s (NASDAQ:) monoclonal antibody cocktail treatment is potentially first-in-class, H.C. Wainwright analyst Vernon Bernardino told investors Wednesday.

Aridis revealed last week that AR-701 was broadly reactive against Omicron (and other Covid-19 variants), SARS (Severe Acute Respiratory Syndrome), MERS Coronavirus (Middle East Respiratory Syndrome Coronavirus) and the common flu, which is a type human coronavirus.  

According to TheFly Bernardino who reiterated a Buy rating and $19 price target for Aridis shares said that Aridis cocktails “bind to the S2 spike subunit of the viral cell membrane fusion mechanism in SARS-CoV-2 variations and also to the Omicron variant with zero loss in affinity when compared to its original Wuhan strain.”

An analyst now sees the start of phase 1 testing as positive for Aridis Pharmaceuticals’ share price in next year. 

H.C. Wainwright made positive remarks about Aridis, following similar comments by Cantor Fitzgerald last week who said that Aridis’ pipeline was “underappreciated”.

It is currently trading down more than 6.8% on Wednesday to $2.04, despite bullish comments.

 

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes and charts. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]